中国药物经济学2024，Vol.19Issue(3)：25-30,6.DOI:10.12010/j.issn.1673-5846.2024.03.004
集中带量采购和医保谈判政策对表皮生长因子受体酪氨酸激酶抑制剂药品采购的影响
The Impact of Volume-based Procurement and Government Reimbursement Negotiation Policies on EGFR-TKI Drug Procurement:A Case Study of Gefitinib and Osimertinib
摘要
Abstract
Objective To evaluate the impact of volume-based procurement and government reimbursement negotiation policies on EGFR-TKI drugs procurement,and to provide empirical reference for the improvement and promotion of volume-based procurement and government reimbursement negotiation.Methods The EGFR-TKI drugs involved in volume-based procurement and government reimbursement negotiation were sorted out,and the appropriate EGFR-TKI drugs were selected.ITS model was used to evaluate the impacts of volume-based procurement and government reimbursement negotiation on DDDc,DDDs and procurement spending.Results After the implementation of the centralized procurement policy,the DDDc and procurement amount of gefitinib decreased significantly(P<0.05),and the DDDs showed a downward trend(P<0.05).After the implementation of the medical insurance negotiation policy,the DDDc of ohitinib drugs decreased significantly(P<0.05),the purchase amount increased significantly(P<0.05),and the upward trend of DDDs increased(P<0.05).Conclusion Centralized procurement and medical insurance negotiation policies have significant effects on EGFR-TKI drug procurement,which can help to reduce patients'economic burden and meet their clinical drug needs.关键词
集中带量采购/医保谈判/表皮生长因子受体酪氨酸激酶抑制剂/间断时间序列分析Key words
Volume-based procurement/Government reimbursement negotiation/EGFR-TKI/Interrupted time series analysis分类
医药卫生引用本文复制引用
易洪彬,石丰豪,蒯丽萍,徐冬艳,韩晟..集中带量采购和医保谈判政策对表皮生长因子受体酪氨酸激酶抑制剂药品采购的影响[J].中国药物经济学,2024,19(3):25-30,6.基金项目
国家医疗保障局(医药服务管理司)立项课题(第2022020号) （医药服务管理司）
